Corrigendum.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 11, p. 725, doi. 10.1177/1758834017743368
- Publication type:
- Article
Works matching IS 17588340 AND DT 2017 AND VI 9 AND IP 11
Results: 6
1
2
Managing hyponatremia in lung cancer: latest evidence and clinical implications.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 11, p. 711, doi. 10.1177/1758834017736210
- By:
- Publication type:
- Article
3
Optimal duration of adjuvant endocrine therapy: how to apply the newest data.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 11, p. 679, doi. 10.1177/1758834017732966
- By:
- Publication type:
- Article
4
Estimating the 95% confidence interval for survival gain between an experimental anti-cancer treatment and a control.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 11, p. 721, doi. 10.1177/1758834017731084
- By:
- Publication type:
- Article
5
X-inactive-specific transcript of peripheral blood cells is regulated by exosomal Jpx and acts as a biomarker for female patients with hepatocellular carcinoma.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 11, p. 665, doi. 10.1177/1758834017731052
- By:
- Publication type:
- Article
6
Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 11, p. 693, doi. 10.1177/1758834017728928
- By:
- Publication type:
- Article